NCT06846268 is a Phase 2 clinical trial of ADG126 in Locally Advanced Colorectal Cancer, sponsored by National University Hospital, Singapore.

Who is sponsoring NCT06846268?

NCT06846268 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT06846268?

Interventions in NCT06846268: ADG126, Pembrolizumab.

What condition does NCT06846268 study?

NCT06846268 studies Locally Advanced Colorectal Cancer.

Is NCT06846268 still recruiting?

NCT06846268 is currently recruiting now. Last updated 25 July 2025.

Last reviewed 2025-07-25 · How we verify

NCT06846268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Recruiting now Phase 2 Last updated 25 July 2025

What this trial tests

Phase 2 trial testing ADG126 in Locally Advanced Colorectal Cancer in 20 participants. Currently enrolling.

Timeline

14 April 2025

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	14 April 2025
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across Singapore

Drugs / interventions tested

ADG126 — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Locally Advanced Colorectal Cancer — all drugs for Locally Advanced Colorectal Cancer →

Sponsor

National University Hospital, Singapore

Who can join

21 and older, any sex, with Locally Advanced Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies.
Kim SY. · · 2026 · PMID 41802306 · DOI 10.3393/ac.2025.01354.0193

Verify or expand the search:

Other trials of ADG126

Trials testing the same drug.

NCT05584670 — A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05405595 — ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
NCT04524871 — A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advan · Phase 1, PHASE2 · recruiting

Other recruiting trials for Locally Advanced Colorectal Cancer

Currently open trials in the same condition.

NCT06550453 — Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutate · Phase 4 · recruiting
NCT05585814 — CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advance · Phase 2 · recruiting
NCT04301557 — PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer · Phase 2 · active not recruiting

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06846268 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 25 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06846268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing